Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by argenx SE

< Previous 1 2 3 Next >
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Announces Results of Annual General Meeting of Shareholders
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx to Present at BofA Securities 2025 Health Care Conference
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx to Present at TD Cowen 45th Annual Healthcare Conference
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Highlights 2025 Strategic Priorities
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
From argenx SE
Via GlobeNewswire
Tickers ARGX
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
Tickers ARGX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.